

Wednesday, 26 November 2025

13:00 – 15:00 Session I: The Bone Marrow Niche in Haemoglobinopathies

13:05-13:25	Ferroptosis and Iron Haemostasis in BM and Inflammation
13:25-13:55	Is SCD a pre-cancerous condition: Clonality in SCD
13:55-14:15	Ineffective erythropoiesis
14:15-14:35	Recent advances in iron homeostasis
14:35-15:00	Round table discussion: are the intrinsic features of these disorders making transplantation difficult?

15:00 – 15:30 Coffee Break

15:30 – 16:00 Keynote Lecture

Advances in non-cellular therapies

16:00 – 17:30 Session II: The problem of NTDT: an orphan haemoglobinopathy

16:00-16:20	Introduction and Natural History of NTDT
16:20-16:40	Mechanism of switch to transfusion dependence
16:40-17:00	Modern treatment of NTDT
17:00-17:30	Round table discussion: is there a role for BMT or gene therapy (non-transplanter point of view)?

17:30 – 18:00 Poster Walk

09:30 – 10:00	Roundtable discussion: are all approaches the same?
10:00 – 11:00	Session III (part I): Gene Editing, Gene Therapy, Gene Correction
10:00-10:20	Update on Zynteglo for TDT
10:20-10:40	Update on Lytfia for SCD
10:40-11:00	Update on Casgevy for TDT
11:00 – 11:30	Coffee Break
11:30 – 12:30	Session III (part II): Gene Editing, Gene Therapy, Gene Correction
11:30-11:50	Update on Casgevy for SCD
11:50-12:10	Update on RUBY study for SCD
12:10-12:30	Update on BEACON study for SCD
12:30 – 13:15	Lunch Break
13:15 – 14:15	Industry Symposium
14:15 – 15:45	Session III (part III): Gene Editing, Gene Therapy, Gene Correction
14:15-14:35	Strategies for successful apheresis collection and post dosing care
14:35-14:55	Optimal busulfan delivery
14:55-15:15	Immune reconstitution & long-term care management
15:15-15:35	Real-world experience: REGENT
15:35-15:45	Round table discussion: what are the priorities for a successful programme?
15:45 – 16:15	Coffee Break
16:15 – 17:00	Industry Symposium
17:00 – 18:00	Session IV: Alternative Donor Transplantation
17:00-17:20	PTCy RIC transplantation (<i>for adults & children</i>)
17:20-17:40	Graft manipulation for haemoglobinopathies
17:40-18:00	Patient selection for curative therapies

Friday, 28 November 2025
Main Track

08:00 - 09:30 **Haemoglobinopathies Working Party Annual Meeting Business Meeting**

Open to all.

09:30 – 11:00 **Session V: Resource Limited Setting**

09:30-09:45 Challenges & priorities of allogeneic transplantation in Tanzania

09:45-10:00 Challenges & priorities of allogeneic transplantation in Nigeria

10:00-10:15 Challenges & priorities of allogeneic transplantation in unequal settings

10:15-10:30 Does gene therapy have a role in resource limited setting

10:30-11:00 Roundtable discussion: is the role for curative therapies in resource limited settings?

11:00 – 11:30 **Coffee Break**

11:30 – 13:00 **Session VI: Alternative Donor Transplantation-Improving Outcomes**

11:30-11:50 The role of AI in transplantation

11:50-12:10 Cerebrovascular disease: reversibility or stabilisation?

12:10-12:30 Utility and outcomes of transplantation of psychometric tests

12:30-12:50 Reversibility of iron damage

12:50-13:00 Effect of BMT on sickle cell disease-related organ complications

13:00 – 13:30 **Farewell Lunch**